

Characterization of NADase-Inactive NAD⁺ Glycohydrolase in *Streptococcus pyogenes*

Ichiro Tatsuno, Masanori Isaka, Tadao Hasegawa

Department of Bacteriology, Graduate School of Medical Sciences, Nagoya City University,
Nagoya, Japan

Email: tadaoh@med.nagoya-cu.ac.jp

Received December 7, 2012; revised January 8, 2013; accepted February 10, 2012

ABSTRACT

Background: *Streptococcus pyogenes* secretes NAD⁺ glycohydrolase (NADase, also known as SPN or Nga). All *S. pyogenes* strains examined to date possess the gene that encodes SPN (*spn*), but some strains produce SPN that lacks detectable NADase activity. Although there is much evidence to support that SPN's NADase activity contributes to virulence, there is very little evidence that NADase-inactive SPN has detectable functions. **Results:** In order to characterize the NADase-inactive SPN, we firstly attempted to clone the NADase-inactive *spn* allele in *Escherichia coli*. Although we obtained recombinants which were shown to have the correct size insert, all had some mutations in the *spn* allele. Therefore, we attempted to change the mutated nucleotides back to the original nucleotides. While a nucleotide mutagenesis (inverse PCR method) easily changed a target nucleotide of control genes back to the original nucleotides, the mutations of NADase-inactive *spn* allele were never successfully converted back to the original nucleotides. Finally the mutant *spn* alleles were sub-cloned into another vector (pLZ12-Km2), which is maintained in both *E. coli* and *S. pyogenes*. The resultant plasmids were subjected to nucleotide mutagenesis using inverse PCR; the resultant mutagenized plasmid DNAs were used to transform both *E. coli* and *S. pyogenes* strains. We observed successful nucleotide substitutions back to the original *spn* nucleotide sequence in *S. pyogenes* transformants, but not in *E. coli* transformants. Thus, the NADase-inactive *spn* allele was successfully cloned in *S. pyogenes*, but not in *E. coli*. However, we could not find an association with NADase-inactive *spn* allele and virulence in a mouse infection model. **Conclusions:** These results suggest that NADase-inactive *spn* allele has some toxic effect to *E. coli*, but not *S. pyogenes*. This effect may be due to an as of yet unknown function attributable to NADase-inactive SPN.

Keywords: *Streptococcus pyogenes*; NAD⁺ Glycohydrolase; NADase; SPN; Streptococcal; SF370

1. Introduction

Streptococcus pyogenes is a gram-positive bacterium that infects the upper respiratory tract, including the tonsils and pharynx, and is responsible for post-infectious diseases such as rheumatic fever and glomerulonephritis. In addition, *S. pyogenes* causes severe invasive disease including necrotizing fasciitis [1-6]. The molecular mechanisms that the organism utilizes to cause these diseases are not yet elucidated fully. To analyze these mechanisms, it is important to characterize the virulence factors of *S. pyogenes* fully. *S. pyogenes* secretes several distinct proteins such as superantigens, DNases, streptokinase, cysteine proteinase SpeB, C5a peptidase, and streptococcal inhibitor of complement-mediated lysis (Sic) [7,8]. Several of these proteins have been identified as virulence factors and analyzed in detail, and others are still not yet fully characterized. NAD⁺ glycohydrolase (NADase, also known as SPN or Nga) is one of the secreted proteins which should be further characterized.

SPN is known as the host attacking enzymatic toxin produced by *S. pyogenes* that shows cytotoxic effects to keratinocytes *in vitro* experiment [9,10]. SPN is also demonstrated toxicity in bacterial cells. To counteract this toxicity, *S. pyogenes* encodes *ifs* gene whose product (IFS) is an endogenous inhibitor of NADase activity and is localized in the bacterial cytoplasmic compartment. Inside the *S. pyogenes* bacterial cell, SPN precursor exists as an inactive complex with IFS [11,12].

Although the SPN had been found long ago [13], initial studies on SPN were hindered by the fact that it was not possible to clone *spn* in *Escherichia coli* which is a commonly used bacterial host for genetic research (due to bacterial death) [11]. In the study conducted by Meehl *et al.* [11], in which *ifs* gene was discovered to exist as a *spn-ifs* operon, they were able to resolve this cloning toxicity issue when the *spn* gene was successfully cloned into a plasmid together with *ifs* (as a *spn-ifs* operon) and subsequently introduced into *E. coli*. The cytotoxicity of

SPN is believed to depend on NADase activity; for example, the hypothesis has been put forth that depletion of cellular NAD⁺ through the enzymatic action of SPN induces host cell death [14]. Meanwhile, it has been demonstrated that some strains produce SPN that lack detectable NADase activity [11,15-17]. The presence of an aspartic acid instead of a glycine at amino acid residue 330 (G330D polymorphism) has been associated with loss of SPN NADase activity [18,19]. Additionally, *ifs* genes degrade into pseudogenes in strains with the NADase-inactive SPN subtype, suggesting that the subtypes no longer lose the self-toxicity to require the functional IFS [11,19]. In contrast, the study using statistically sufficient number of NADase-inactive strains revealed that the *spn* alleles themselves never degrade into pseudogenes [19]. Based on these findings suggesting that SPN has a hidden NADase-independent function [19], we were prompted to re-evaluate the role of NADase-inactive SPN in *S. pyogenes* pathogenesis.

2. Materials and Methods

2.1. Ethic Statement

All animal studies conducted comply with federal and institutional (the Committee on the Ethics of Animal Experiments of the Nagoya City University) guidelines. The protocol was approved by the Committee on the Ethics of Animal Experiments of the Nagoya City University (Permit Number: H23M-07). All efforts were made to minimize suffering.

2.2. Bacterial Strains

Streptococcus pyogenes strains 1529 and GT01 isolated as causative organisms from invasive diseases patients in Japan possess NADase active SPN [18,20]. *S. pyogenes* (GAS) strain SF370, which is prevalent as the database reference isolate (accessionNC_002737), was provided by the courtesy of J. J. Ferretti [21,22]. Streptococcal strains were cultured in brain heart infusion (E-MC62, EIKEN Chemical Co., Tokyo, Japan) supplemented with 0.3% yeast extract (BD, Sparks, MD, USA) (BHI-Y) broth unless otherwise described.

2.3. Cloning Experiment of *Spn*_{SF370} Gene

The *spn*_{SF370} of *S. pyogenes* strain SF370 and the other control DNAs were amplified by PCR with Extaq DNA polymerase (Takara Bio, Ohtsu, Japan) using the corresponding primers listed in **Table 1**. pGEM[®]-T Easy vector system (Promega, Madison, WI, USA) was used for cloning of the PCR products purified by Gel extraction kit (Qiagen, Hilden, Germany). The high copy-number pGEM[®]-T Easy vector contains T7 and SP6 RNA poly-

Table 1. Sequences of primers used in this study.

(Cloning primers^a)	
<i>spn</i> _{SF370} (1.5 kbp)	
ngaGT-n1Nhe	5'-GGCTAGCGAACAGATGTGAAGGTTCT G-3'
nga-c4xho	5'-CCTCGAGTTGGCACCTTATACATATT G-3'
<i>spn-ifs</i> _{GT01} (2.1 kbp)	
Nga-n4Eco	5'-GGAATTCATGAGAAACAAAAAAGTA AC-3'
slo2	5'-ATCATCCGTTTTCTGACCTG-3'
<i>covRS</i> _{GT01} (2.6 kbp)	
csrRn2	5'-CTTTAGAGAATATGGTTACT-3'
csrSc2	5'-GTAATTACATTTTGGACAAC-3'
<i>covRS</i> ₁₅₂₉ (2.6 kbp)	
csrRn2	5'-CTTTAGAGAATATGGTTACT-3'
csrSc2	5'-GTAATTACATTTTGGACAAC-3'
<i>spy</i> 1193 (1.0 kbp)	
MG5005-spy1193F	5'-ATGTCCTATCTCATGGTAAGG-3'
MG5005-spy1193R	5'-ACCTATAAACAGTCAATGAG-3'
<i>recA</i> _{SF370} (0.3 kbp)	
SPYrecA-F	5'-CGAAGTCGTTTGGATGTGCGC-3'
SPYrecA-R	5'-CCTGAACTTTTGTCTGCGAC-3'
<i>vicRK</i> ₁₅₂₉ (2.8 kbp)	
Spy528-n1	5'-GTTGATGCAGAAGTAGTGACC-3'
Spy0528-c2	5'-GGCATCAAGCTTACCTAGCA-3'
<i>vicK</i> ₁₅₂₉ (1.7 kbp)	
Spy528-n5	5'-CGGTTGATGTGACTGTTTCG-3'
Spy0528-c2	5'-GGCATCAAGCTTACCTAGCA-3'
<i>spn-ifs</i> _{SF370} (2.0 kbp)	
ngaGT-n1Nhe	5'-GGCTAGCGAACAGATGTGAAGGTTCT G-3'
nga-c8xho	5'-CCGCTCGAGTTA GACATGTCCTTCATACC-3'
<i>spn-ifs</i> _{SF370} (2.1 bp)	
ngaGT-n1Nhe	5'-GGCTAGCGAACAGATGTGAAGGTTCT G-3'
IFS-R(EcoRI)	5'-GTTTGTTCGAATTCGCATTAGCAG-3'
<i>spn-ifs</i> _{SF370} (2.2 kbp)	
ngaGT-n1Nhe	5'-GGCTAGCGAACAGATGTGAAGGTTCT G-3'
slo-c2	5'-ATCATCCGTTTTCTGACCTG-3'
(Inverse PCR primers)	
nga(SF370)-F	5'-AGAAACAAAAAAGTAACATTAG-3'
nga(SF370)-R	5'-CATGTAAACCACCTTATATTA-3'

Continued

nga(SF370)-F2	5'-ATAGTTACTTAAAAATAATATA-3'
nga(SF370)-R2	5'-ACATTAGCAAATAGTTTTTGTGTC-3'
vicK-F	5'-ACCCAATTAGCAGTAGAGATGA-3'
vicK-R	5'-TACTTGATTATCAATCCGAGA-3'

^aName of insert DNA fragment amplified by PCR (the expected size), used primer name and the sequence were described. The two PCR products of *recA*_{SF370} and *spy*1193₁₅₂₉ contain a part of the gene, respectively, whereas the others have the hole genes indicated. *spn*_{SF370} and *recA*_{SF370} are PCR products from strain SF370. *spn-ifs*_{G701}, and *covRS*_{G701} are PCR products derived from strain GT01. *spy*1193₁₅₂₉, *covRS*₁₅₂₉, *vicRK*₁₅₂₉, and *vicK*₁₅₂₉ are PCR products derived from strain 1529. *S. pyogenes* strain SF370 encode NADase-inactive SPN, whereas strains 1529 and GT01 encode NA-Dase-active SPN.

merase promoters flanking a multiple cloning region within the α -peptide coding region of the enzyme β -galactosidase

<http://www.promega.com/~media/files/resources/protocols/technical%20manuals/0/pgem-t%20and%20pgem-t%20easy%20vector%20systems%20protocol.pdf?la=en>. In the pGEM[®]-T Easy vector system, recombinant clones are allowed to be directly identified by blue/white color screening on indicator plates.

For *spn*_{SF370}-cloning, we obtained three recombinants that have the correct size insert in the corresponding plasmids (named pGEM-*spn*_{SF370}26, pGEM-*spn*_{SF370}32, and pGEM-*spn*_{SF370}13; see Result section for additional detail on the creation of these plasmids).

2.4. Nucleotide Substitution by Inverse PCR

Primstar Taq DNA polymerase (Takara) was used for the inverse PCR described previously [18]. Primers used are listed in Table 1. PCR product was self-ligated and used to transform *E. coli* strain DH5 α .

2.5. Construction of pLZ12-Km2 Derivatives

The inserts of pGEM-*spn*_{SF370}26, pGEM-*spn*_{SF370}32, and pGEM-*spn*_{SF370}13 were digested with *Eco*RI, and subcloned into pLZ12-Km2 to yield pLZ-*spn*_{SF370}26, pLZ-*spn*_{SF370}32, and pLZ-*spn*_{SF370}13, respectively.

2.6. Creation of *Spn* Mutant of Strain SF370

E. coli JM109 was used to propagate plasmid constructions. Non-polar inactivated mutant of *spn* was constructed via double-crossover allelic replacement in the chromosome of *S. pyogenes* SF370. To construct the plasmid for the *spn* knockout mutant, the 5' end of *spn* (fragment 1) was amplified with oligonucleotide primers ngaGT-n1

(5'-GGCTAGCGAACAGATGTGAAGGTTCTG-3')

with an *Nhe*I restriction site and ngaGT-c1

(5'-TCCCCCGGGTTTCTCATGTAAACCACCT-3')

with an *Sma*I restriction site, and the 3' end of *spn* (fragment 2) was amplified with ngaGT-n2

(5'-TCCCCCGGGATAGGAAGTAACAATATGT-3')

with an *Sma*I restriction site and ngaGT-c2

(5'-GGACTAGTATGTTAGCTTTCAATTGGGT-3')

with an *Spe*I restriction site. Oligonucleotides ngaGT-n1, ngaGT-c1, ngaGT-n2 and ngaGT-c2 contained a restriction site for *Nhe*I, *Sma*I, *Sma*I and *Spe*I, respectively, (shown in underline in the primer sequence). Fragment 2 was digested with *Sma*I and *Spe*I for insertion into multi-cloning site 2 of the pFW12 plasmid [23]. The resulting plasmid was then digested with *Nhe*I and *Sma*I, and both the *spc*2 DNA fragment containing *aad*9 (promoter less spectinomycin resistant gene), which was obtained from a *Sma*I digested fragment of pSL60-2 [24], and the *Nhe*I-*Sma*I-digested fragment 1 were inserted. This plasmid, pFW12::(*spn*::*aad*9), was a suicide vector for *S. pyogenes*. For the preparation of competent cells, strain SF370 was harvested at early- to mid-log phase (OD₆₆₀ = 0.4 to 0.5) and washed twice with 0.5 M sucrose buffer. The constructed suicide vector pFW12::(*spn*::*aad*9) was used to transform strain SF370 by electroporation. The conditions of electroporation were 1.25 kV/mm, 25 μ F capacitance and 200 Ω resistance, using Gene Pulser II (Bio-Rad, Hercules, CA, USA). After incubation at 37°C for 3 h, competent cells were spread onto BHI agar plates containing 0.3% yeast extract and spectinomycin (final concentration 100 μ g/ml). Selected colonies on the plates were cultured. Cultured bacteria were washed once with saline, resuspended in 10 mM Tris, 1 mM EDTA and boiled for 10 min. Genomic DNA was obtained from the supernatant of boiled bacteria. The double-crossover replacement was analyzed using genomic DNA by PCR and successful double-crossover replacement was further confirmed by DNA sequencing.

2.7. Mouse Model of Invasive Skin Tissue Infection

The ability of *S. pyogenes* to cause local skin lesions and necrosis in mice after skin inoculation was assessed using a procedure similar to that described elsewhere [25]. In brief, 3-week-old female ICR mice (10 - 12 g) were anesthetized with sevoflurane, and the skin of the left flank was bared by separating hair with alcohol swab, unless otherwise indicated. Bacteria (0.2 ml; 2 \times 10⁷ cfu per mouse) grown in BHI-Y were injected with a 27-gauge needle just under the surface of the skin so that a superficial bleb was raised immediately below the skin surface. The number of colony-forming units injected was verified for each experiment by plating bacteria on BHI-Y or sheep blood agar plates (with or without kanamycin) and counting colony-forming units. Lesion sizes (length \times width) were measured, with the length determined as the longest dimension of the lesion at day

3 or at the death time point.

Bacteria were recovered from the mice which survived until day 8. For mouse blood samples: 100 μ l of blood from the heart was spread on a sheep blood agar plate. For the spleen samples: Spleen was homogenized and suspended with 100 μ l of PBS and spread on a sheep blood agar plate. β -hemolysis positive colonies were calculated. Two colonies per plate were randomly selected and inoculated into BHI-Y broth supplemented with or without 50 μ g/ml spectinomycin for microscopic analysis to confirm coccus morphology and chain arrangements characteristic of Streptococcal species.

All animal procedures were approved by the Institutional Animal Care and Use Committee at Nagoya City University.

2.8. Statistical Analysis

Data collected for virulence to mouse (survival days) were assessed using a log-rank comparison described previously [20]. R software was used for statistical analysis <http://bioinf.wehi.edu.au/software/russell/logrank/>. *P*-value ≤ 0.05 was considered significant.

3. Results

3.1. Cloning of *Spn*_{SF370} Gene into a pGEM[®]-T Easy Vector

S. pyogenes strain SF370 is a representative among NADase negative strains. In order to evaluate the role of NADase-inactive SPN, we firstly attempted to clone the *spn*_{SF370} gene of the strain SF370 into a pGEM[®]-T Easy vector in *E. coli* strain DH5 α without support of the *ifs*_{SF370} gene. The vector and the strain DH5 α are compatible with the blue/white color screening for recombinants. Typically, we see about half of the transformants showing white color under our experimental condition when a DNA insert without toxicity to *E. coli* is used. We show data from two representative experiments in **Table 2** (40.9% and 44.4% white colonies for *recA*_{SF370} and *spy*1193₁₅₂₉, respectively; these genes have been cloned for our other studies around the same time as this study). In contrast, the four cloning experiments using the insert encoding *spn*_{SF370} showed only 8.7%, 27.6%, 31.8% and 0.8% white colonies (**Table 2**). Eighty-five of the white colonies derived from the *spn*_{SF370}-insert were randomly selected for further plasmid analysis (named as pGEM-*spn*_{SF370}1 to 85), and only three colonies (4%) possessed the correct size insert (1.5 kbp) in the corresponding plasmids (pGEM-*spn*_{SF370}26, pGEM-*spn*_{SF370}32, and pGEM-*spn*_{SF370}13; see **Table 3** and **Figure S1**). In contrast, in the experiments using control inserts, more than 50% of white colonies had the correct size inserts: 94%, 67%, 100%, 100%, 86%, 57% and 88% for *spn-ifs*_{GT01}, *recA*_{SF370}, *spy*1193₁₅₂₉, *covRS*_{GT01}, *covRS*₁₅₂₉,

*vicRK*₁₅₂₉ and *vicK*₁₅₂₉, respectively (**Table 3**).

For the *spn*_{SF370}, the insert of the three plasmids (pGEM-*spn*_{SF370}26, pGEM-*spn*_{SF370}32, and pGEM-*spn*_{SF370}13) were sequenced, and the following mutations were found: substitution of the start codon ATG to ACG in pGEM-*spn*_{SF370}26, the second codon AGA (Arg) to TGA (stop) in pGEM-*spn*_{SF370}32, and an adenine nucleotide was substituted to a guanine (G) at nucleotide 34 upstream from the adenine (A) of the start codon in pGEM-*spn*_{SF370}13, respectively (see most right column in **Table 3**). We propose these mutations may have been introduced for the following reasons: 1) A spontaneous mutation is often inserted in DNA fragment amplified by PCR or 2) *spn*_{SF370} gene is toxic to *E. coli* cells, so mutations to make the gene inactive were given for a natural survival advantage. In order to examine those possibilities,

Table 2. The numbers of blue/white colonies.

PCR product ^a		W ^b	B ^b	W + B ^b	w/w + B ^b ^c
<i>spn</i> _{SF370}	exp. 1	21	220	241	8.7
	exp. 2	107	280	387	27.6
	exp. 3	1070	2300	3370	31.8
	exp. 4	21	2725	2746	0.8
	Total ^d	1219	5525	6744	18.1
<i>recA</i> _{SF370}	exp.1	2523	3650	6173	40.9
<i>spy</i> 1193 ₁₅₂₉	exp.1	1602	2004	3606	44.4
<i>vicRK</i> ₁₅₂₉	exp.1	31	4400	4431	0.7
<i>vicK</i> ₁₅₂₉	exp.1	106	3200	3306	3.2

^aPCR products of *recA*_{SF370} and *spy*1193₁₅₂₉ contain a part of the gene, respectively, whereas the others have the hole genes indicated. ^bThe numbers of white (W), blue (B), and the total (W + B) colonies. ^c% white colonies. ^dsum of the colony numbers from 4 experiments.

Table 3. Cloning of the insert containing *spn*_{SF370} gene into pGEM-T easy vector.

Insert DNA ^a	Insert + (%)	P ^b	No mutation ^c
<i>spn</i> _{SF370}	3/85 (4)	NA	0/3
<i>spn-ifs</i> _{GT01}	17/18 (94)	<0.01	2/8
<i>recA</i> _{SF370}	2/3 (67)	<0.01	2/2
<i>spy</i> 1193 ₁₅₂₉	2/2 (100)	<0.01	N.D.
<i>covRS</i> _{GT01}	4/4 (100)	<0.01	1/4
<i>covRS</i> ₁₅₂₉	6/7 (86)	<0.01	1/6
<i>vicRK</i> ₁₅₂₉	4/7 (57)	<0.01	0/4
<i>vicK</i> ₁₅₂₉	7/8 (88)	<0.01	0/7

^aAs a control for *spn*_{SF370}, seven examples *spn-ifs*_{GT01}, *recA*_{SF370}, *spy*1193₁₅₂₉, *covRS*_{GT01}, *covRS*₁₅₂₉, *vicRK*₁₅₂₉, and *vicK*₁₅₂₉ were shown. See **Table 1** about information for the insert DNAs. ^bZ-test was used in order to compare with *spn*_{SF370}. ^cNumber of insert without any mutation/number of sequenced insert DNA.

we attempted to change the mutated nucleotides back to the original nucleotides using the inverse PCR method described previously [18]. We performed inverse PCR

with primers nga(SF370)-F and nga(SF370)-R (Tables 1 and 4) constructed to substitute the mutated second codon of the *spn_{SF370}* on pGEM-*spn_{SF370}*32 to the original

Table 4. Physical maps of primers used for inverse PCR were shown.

<i>spn_{SF370}</i>	
WT ^a	AATAATATAAGGTGGTTTAC <u>ATG</u> <u>AGAAACAAAAA</u> AGTAACATTAG
No. 32 ^b	AATAATATAAGGTGGTTTAC <u>ATG</u> <u>TGAAACAAAAA</u> AGTAACATTAG Primer: nga(SF370)-F Primer: nga(SF370)-R
32 - 1	AATAATATAAGGTGGTTTAC <u>ATG</u>
32 - 2	AATAATATAAGGTGGTTTAC <u>ATA</u> <u>AGAAACAAAAA</u> AGTAACATTAG
32 - 4	AATAATATAAGGTGGTTTAC <u>ATG</u> <u>GAAACAAAAA</u> AGTAACATTAG
32 - 8	AATAATATAAGGTGGTTTAC <u>AT</u> <u>TGAAACAAAAA</u> AGTAACATTAG
32 - 9	AATAATATAAGGTGGTTTAC <u>ATG</u> <u>GAAACAAAAA</u> AGTAACATTAG
32 - 12	AATAATATAAGGTGGTTTAC <u>ATG</u> <u>GAAACAAAAA</u> AGTAACATTAG
No. 26 ^c	AATAATATAAGGTGGTTTAC <u>ACG</u> <u>AGAAACAAAAA</u> AGTAACATTAG Primer: nga(SF370)-F Primer: nga(SF370)-R
26 - 1	AATAATATAAGGTGGTTTAC <u>ATG</u> <u>GAAACAAAAA</u> AGTAACATTAG
26 - 2	AATAATATAAGGTGGTTTAC <u>AT</u> <u>AGAAACAAAAA</u> AGTAACATTAG
WT ^d	GACAAAAACTATTTGCTAATGT ATAGTTTACTTAAAAATAATATAAG
No. 13 ^e	GACAAAAACTATTTGCTAATGT <u>GTAGTTTACTTAAAAA</u> TAATATAAG Primer: nga(SF370)-F2 Primer: nga(SF370)-R2
13 - 1	GACAAAAACTATTTGCTAA ATAGTTTACTTAAAAATAATATAAG
13 - 3	GACAAAAACTATTTGCTAAT AGTTTACTTAAAAATAATATAAG
13 - 4	GACAAAAACTATTTGCTAATGT <u>GTAGTTTACTTAAAAA</u> TAATATAAG
13 - 5	GACAAAAACTATTTGCTAATGT CTAGTTTACTTAAAAATAATATAAG
<i>vicRK₁₅₂₉</i>	
WT ^f	GTCTCGGATTGATAATCAAGTA <u>ACCCAATTAGCAGTAGAGATGAC</u>
No. 11 ^g	GTCTCGGATTGATAATCAAGTA <u>GCCCAATTAGCAGTAGAGATGAC</u> Primer: vicK-F Primer: vicK-R
11 - 1	GTCTCGGATTGATAATCAAGTA <u>CCCAATTAGCAGTAGAGATGAC</u>
11 - 2	GTCTCGGATTGATAATCAAGTA <u>ACCCAATTAGCAGTAGAGATGAC</u>
No. 28 ^h	GTCTCGGATTGATAATCAAGTA <u>GCCCAATTAGCAGTAGAGATGAC</u> Primer: vicK-F Primer: vicK-R
28 - 1	GTCTCGGATTGATAATCAAGTA <u>ACCCAATTAGCAGTAGAGATGAC</u>
28 - 2	GTCTCGGATTGATAATCAAGTA <u>ACCCAATTAGCAGTAGAGATGAC</u>

The mutated nucleotides were attempted to change back to the original nucleotides. Primers used for the inverse PCR were shown by arrows. The primer' nucleotide sequences were also shown in Table 1. Unsuccessful substitutions were shown in italic type. ^aOriginal nucleotide sequence of the junction site. The adenine and thymine nucleotides which were substituted in No. 32 and No. 26, respectively, were shown as bold "A" and "T". The start (ATG) and second (AG) codons were underlined. ^bThe mutated thymine nucleotide of the *spn_{SF370}* on pGEM-*spn_{SF370}*32 was shown as bold "T". ^cThe mutated cytosine nucleotide of the *spn_{SF370}* on pGEM-*spn_{SF370}*26 was shown as bold "C". ^dOriginal nucleotide sequence of the junction site. The adenine (A) nucleotide, which was substituted in No. 13, was shown in bold type. ^eThe mutated guanine nucleotide on the pGEM-*spn_{SF370}*13 was shown as bold "G". ^fOriginal sequence of the junction site. The adenine nucleotide, which was substituted in No. 11 and No. 28, was shown as bold "A". The 267th codon (ACC) was underlined. ^gThe mutated guanine nucleotide of the *vicK₁₅₂₉* on pGEM-*vicK₁₅₂₉*11 was shown as bold "G". ^hThe mutated guanine nucleotide of the *vicK₁₅₂₉* on pGEM-*vicK₁₅₂₉*28 was shown as bold "G".

codon AGA (R). The amplification product was self-ligated and used to transform *E. coli* strain DH5 α . Plasmids were prepared from randomly selected 14 transformants (named as 32 - 1 to 32 - 14). Five plasmids (32 - 2, 32 - 4, 32 - 8, 32 - 9 and 32 - 12) appeared to possess the correct size insert, whereas the other nine (32 - 1, 32 - 3, 32 - 5, 32 - 6, 32 - 7, 32 - 10, 32 - 11, 32 - 13, and 32 - 14) had the smaller size inserts based on the result seen during agarose gel electrophoresis (data not shown). In addition to the inserts of the five passed plasmids (32 - 2, 32 - 4, 32 - 8, 32 - 9 and 32 - 12), one of the dropped-out plasmids (32 - 1) which was added as a representative (internal) negative-control were sequenced. As shown in **Table 4**, the 32 - 1 had a large deletion and the other five contained a nucleotide mutation or deletion at the junction site. Additionally for pGEM-*spn*_{SF370}26, and pGEM-*spn*_{SF370}13, we attempted to change the mutated nucleotides back to the original nucleotides by using same method with primers nga (SF370)-F and nga (SF370)-R, or primers nga(SF370)-F2 and nga(SF370)-R2 (**Table 4**). Two of the seven pGEM-*spn*_{SF370}26 derivative plasmids (26 - 1 and 26 - 2) prepared from randomly selected transformants (named as 26 - 1 to 26 - 7) appeared to possess the correct size insert. However, both plasmids had a nucleotide deletion at the junction site (**Table 4**). For pGEM-*spn*_{SF370}13, four (13 - 1, 13 - 2, 13 - 4, and 13 - 5) of seven plasmids prepared from randomly selected transformants appeared to possess the correct size insert. However, one plasmid (13 - 4) was same as the original pGEM-*spn*_{SF370}13 and the other three possessed a nucleotides deletion or a nucleotide mutation at the junction site (**Table 4**). We have observed successful substitution of a corresponding nucleotide for more than 50% of the transformants checked in other recent experiments. Two representative examples are shown below. As described above (see **Table 3**), the four and the seven types of pGEM-T easy derivatives having *vicRK*₁₅₂₉ and *vicK*₁₅₂₉ have been previously constructed, respectively (named as pGEM-*vicRK*₁₅₂₉11, pGEM-*vicRK*₁₅₂₉12, pGEM-*vicRK*₁₅₂₉13, pGEM-*vicRK*₁₅₂₉15 and pGEM-*vicK*₁₅₂₉22, pGEM-*vicK*₁₅₂₉23, pGEM-*vicK*₁₅₂₉24, pGEM-*vicK*₁₅₂₉25, pGEM-*vicK*₁₅₂₉26, pGEM-*vicK*₁₅₂₉27, pGEM-*vicK*₁₅₂₉28: each plasmid has a mutation(s) in somewhere of *vicRK*₁₅₂₉ or *vicK*₁₅₂₉). Among the plasmids, pGEM-*vicRK*₁₅₂₉11 and pGEM-*vicK*₁₅₂₉28 which have both a mutation changing the codon 276 of *vicK*₁₅₂₉ gene from a ACC (encoding "T") to a GCC (encoding "A") were used for the control experiments performed with primers vicK-F and vicK-R (**Table 4**). We observed a successful substitution of the corresponding nucleotide in one of two transformants (11 - 1 and 11 - 2) analyzed for pGEM-*vicRK*₁₅₂₉11, two of two transformants (28 - 1 and 28 - 2) in pGEM-*vicK*₁₅₂₉28 (**Tables 4 and 5**). In the case

of *spn*_{SF370} gene, we never observed the expected nucleotide change when using any of three plasmids as template described above (**Tables 4 and 5**). These results suggest that *spn*_{SF370} gene is toxic to *E. coli* cells.

In strain SF370, the *ifs*_{SF370} allele has a nonsense mutation in the codon for leucine 24 to produce a truncated open reading frame [11]. In order to determine whether the truncated *ifs*_{SF370} open reading frame can successfully inhibit the toxicity of *spn*_{SF370} gene in *E. coli* cells, we attempted to clone a *spn-ifs*_{SF370} operon into the pGEM[®]-T Easy vector. The original forward primer ngaGT-n1Nhe previously used for cloning of *spn*_{SF370} gene and three altered reverse primers (nga-c8xho, IFS-R(EcoRI), and slo-c2) to include *ifs* were tested (**Table 1**). However, we did not obtain any recombinants having the expected insert in the size (data not shown).

3.2. Cloning *Spn*_{SF370} Gene into pLZ12-Km2 Vector

We attempted to clone *spn*_{SF370} by using plasmid pLZ12-Km2 instead of pGEM[®]-T Easy. pLZ12-Km2 which has a rolling circle type of replication can be successfully maintained in both *E. coli* and *S. pyogenes* [26]. Firstly, each insert DNA of pGEM-*spn*_{SF370}26, pGEM-*spn*_{SF370}32, and pGEM-*spn*_{SF370}13 was subcloned into pLZ12-Km2 (named as pLZ-*spn*_{SF370}26, pLZ-*spn*_{SF370}32, and pLZ-*spn*_{SF370}13 respectively). By using these plasmids as template for inverse PCR, we attempted to change the mutated nucleotides back to original nucleotides. Ligated DNA was introduced into *E. coli* strain DH5 α and *S. pyogenes* strain 1529. We obtained a handful of and many transformants in *E. coli* and *S. pyogenes*, respectively. Therefore, all *E. coli* transformants obtained were investigated, while only a subset of transformants in *S. pyogenes* were further investigated. We did not observe successful substitution in any of the *E. coli* transformants

Table 5. Substitution of the mutated nucleotides back to the original one.

Template ^a	Recovered ^b	
	<i>E. coli</i>	<i>S. pyogenes</i>
pGEM- <i>spn</i> _{SF370} 32	0/14 (0%)	N/A
pGEM- <i>spn</i> _{SF370} 26	0/7 (0%)	N/A
pGEM- <i>spn</i> _{SF370} 13	0/7 (0%)	N/A
pGEM- <i>vicRK</i> ₁₅₂₉ 11	1/2 (50%)	N/A
pGEM- <i>vicK</i> ₁₅₂₉ 28	2/2 (100%)	N/A
pLZ- <i>spn</i> _{SF370} 32	0/2 (0%)	1/2 (50%)
pLZ- <i>spn</i> _{SF370} 26	0/5 (0%)	5/5 (100%)
pLZ- <i>spn</i> _{SF370} 13	0/5 (0%)	1/5 (20%)

^aPlasmids used for inverse PCR. ^bNumber of plasmid having the successful substitution/number of the analyzed plasmid (%). N/A: not applicable.

regardless of the plasmid templates used (Table 5). We did observe successful substitution in the *S. pyogenes* transformants for all three of the plasmid templates used (Table 5). Finally, the *spn_{SF370}* gene was successfully cloned only when *S. pyogenes* strain 1529 was used as host. These results suggest that the insert DNA encoding *spn_{SF370}* has some toxic effect to *E. coli*, but not *S. pyogenes*.

3.3. Construction and Analysis of SF370Δspn

The toxicity of *spn_{SF370}* could be related with Riddle *et al.*'s claim that SPN has a NADase-independent function. In order to further explore this hypothesis, *spn_{SF370}* gene was replaced with an antibiotics marker and the resulting strain SF370Δspn was used to infect mice.

When the SF370Δspn was inoculated in mouse skin, the mortality (36%) of the infected mice was not significantly different from the infection with the parental strain SF370 (14%) ($p = 0.214$, see Table 6). In addition, there were not significant differences in the lesion sizes of mouse skin infected with either SF370Δspn or strain SF370 (data not shown). Furthermore, bacteria were recovered from blood and spleen of the surviving mice on day 8 (Table 7). The bacterial number recovered from the mice infected with SF370Δspn was not reduced compared with the case infected with the parental strain SF370.

4. Discussion

Riddle *et al.* suggested that SPN has both NADase-dependent and NADase-independent function [19]. Cloning of a target gene is the first step in studying the function of genes in many biological researches. Therefore, in order to explore what is the NADase-independent function, we attempted to clone the *spn_{SF370}* gene encoding the NADase-inactive SPN in *Escherichia coli*. We initially expected that cloning this gene into *E. coli* would be simple, because it was believed that the toxicity of SPN for bacterial cells is associated with the NADase activity [11,19]. But in actuality, we were not able to clone the gene in *E. coli*, suggesting that *spn_{SF370}* gene has some NADase-independent toxicities to *E. coli* cells compared with several controls used in this study. Therefore, we were forced to explore another strategy to achieve successful cloning of the gene. We tested *ifs_{SF370}* gene as the first strategy, because *spn* alleles encoding NADase-active SPN subtype have ever been cloned by aid of *ifs* gene in *E. coli* [11,12,20]. Consequently, *spn-ifs_{SF370}* also was not able to be cloned in *E. coli*. This result could be explained by the fact that *ifs_{SF370}* has been previously shown to degrade into a pseudogene [19]. Additionally, we took into account that IFS does not necessarily provide a perfect suppression of the self-toxicity of the

Table 6. Virulence (Mortality) to mouse of SF370Δspn.

	Mortality (death/trial)
SF370 wt	14% (2/14)
SF370Δspn	36% (5/14)

Mortality was determined on Day 8 ($P = 0.214$ for comparison of survival days).

Table 7. Bacterial number (CFU) recovered from the survived mice.

	Blood ^a	Spleen ^b
wt-1	9	>10 ³
wt-2	0	0
wt-3	0	0
wt-4	0	0
wt-5	0	5
wt-6	0	0
wt-7	0	>10 ³
wt-8	0	1
wt-9	0	0
wt-10	0	0
wt-11	0	4
wt-12	0	0
Δspn-1	0	>10 ³
Δspn-2	0	>10 ³
Δspn-3	0	>10 ³
Δspn-4	0	52
Δspn-5	44	930
Δspn-6	0	0
Δspn-7	0	>10 ³
Δspn-8	0	15
Δspn-9	0	9

The mice, which survived until day 8 in Table 6, were used. ^a100 μl of blood from heart was spread on a sheep blood agar plate. ^bSpleen was homogenized and suspended with 100 μl of PBS. All the PBS (100 μl) was spread on a sheep blood agar plate. Two colonies per plate were randomly selected, and we observed coccus morphology and chain arrangements characteristic of Streptococcal species by using a microscope. In addition, the colonies derived from the mice challenged with SF370Δspn were spectinomycin-resistant, whereas the colonies from the mice challenged with the parental strain SF370 were sensitive to spectinomycin.

NADase-active SPN as described below. We had attempted to clone *spn_{GT01}* gene encoding NADase-active SPN by aid of *ifs_{GT01}* gene in *E. coli* in the previous study [20]. For this experiment, four different forward primers were used to amplify the *spn-ifs_{GT01}* genes with the reverse primer slo2 (Figure S2). While the first forward

primer (Nga-n4Eco) does not contain any upstream DNA sequences encoding a potential ribosome-binding site, the other three would contain longer upstream DNA sequences (118, 185 and 287 bp respectively as shown in the **Figure S2**). For the latter three primers, we did not obtain any transformants containing the prospective plasmids. Using the Nga-n4Eco we obtained the resulting 13 transformants having the plasmids (pNGIe1 to 13, respectively) in which only the coding regions of *spn_{GT01}* were cloned. In addition, all the *spn_{GT01}* genes (of pNGIe1 to 13) were oriented in the opposite direction as the *lacUV5* promoter on the pGEM[®]-T Easy vector. These selections for the upstream DNA sequences length and the orientation of the cloned *spn_{GT01}* may decrease the amount of NADase produced, because it has been already shown that at least addition of 16 bp and 26 bp upstream DNA sequences to *spn_{GT01}* resulted in the increased production of NADase activity in our previous study [20]. In that study, therefore, we hypothesized that plasmids producing NADase at lower level were selected for due to the potential toxicity of over produced NADase to bacterial cell. However we were not able to explain the reason why *ifs_{GT01}* gene did not sufficiently suppress the potential toxicity. Now, we propose a hypothesis that IFS_{GT01} could not inhibit the potential NADase-independent (self-) toxicity of SPN_{GT01} because IFS_{GT01} was inhibitor of NADase activity.

It is possible that *S. pyogenes* has some mechanism to manage the NADase-independent toxic properties of SPN as well as IFS for the NADase-dependent toxic property. Therefore, we attempted to use *S. pyogenes* as a host for cloning of *spn_{SF370}* gene. For this experiment, we used the *E. coli-Streptococcus* shuttle vector pLZ12-Km2 which copy number would be intermediate (personal communication with Dr. June R. Scott). The *spn_{SF370}* gene was successfully cloned in *S. pyogenes*, but not in *E. coli*. These results suggested that *S. pyogenes* has a mechanism for management of NADase-independent toxic properties of SPN that is lacking in *E. coli*.

The toxicity of *spn_{SF370}* could be related with Riddle *et al.*'s claim that SPN has a NADase-independent function. In order to further investigate the hypothetical function, we used the experimental mouse infection model. Based on our findings, we could not find any direct evidence for the hypothetical function. This may be related with the limitation of this experimental model, since humans are the only natural host for *S. pyogenes*. However, there was an unexpected result. It seemed that *spn_{SF370}* mutants survived better in the spleen (**Table 7**). About this, we have only one positive idea. Strain SF370 is not hyper virulent, compared with clinical isolates from severe invasive disease. NADase inactive SPN_{SF370} might contribute to the low virulence of the SF370. Hyper virulence is not only

strategy in order to survive in host, because non-pathogenic, but not enterohemorrhagic, *E. coli* is living persistently in all human gut.

5. Conclusion

We have presented further supportive evidence that SPN has a NADase-independent function.

6. Acknowledgements

We thank Laura Leverton for critical reading of the manuscript and Hideyuki Matsui for technical assistance. This study was supported by JSPS KAKENHI Grant number 21790425 and KK24590531, a grant from Ohyauma Health Foundation, and a grant from the 24th General Assembly of the Japanese Association of Medical Sciences (Medical Science Promotion Fund).

REFERENCES

- [1] L. A. Cone, D. R. Woodard, P. M. Schlievert and G. S. Tomory, "Clinical and Bacteriologic Observations of a Toxic Shock-Like Syndrome Due to *Streptococcus pyogenes*," *New England Journal of Medicine*, Vol. 317, No. 3, 1987, pp. 146-149.
[doi:10.1056/NEJM198707163170305](https://doi.org/10.1056/NEJM198707163170305)
- [2] C. W. Hoge, B. Schwartz, D. F. Talkington, R. F. Breiman, E. M. MacNeill and S. J. Engler, "The Changing Epidemiology of Invasive Group A Streptococcal Infections and the Emergence of Streptococcal Toxic Shock-Like Syndrome. A Retrospective Population-Based Study," *JAMA*, Vol. 269, No. 3, 1993, pp. 384-389.
[doi:10.1001/jama.1993.03500030082037](https://doi.org/10.1001/jama.1993.03500030082037)
- [3] B. Schwartz, R. R. Facklam and R. F. Breiman, "Changing Epidemiology of Group A Streptococcal Infection in the USA," *Lancet*, Vol. 336, No. 8724, 1990, pp. 1167-1171.
[doi:10.1016/0140-6736\(90\)92777-F](https://doi.org/10.1016/0140-6736(90)92777-F)
- [4] D. L. Stevens, "Invasive Group A Streptococcal Infections: The Past, Present and Future," *Pediatric Infectious Disease Journal*, Vol. 13, No. 6, 1994, pp. 561-566.
[doi:10.1097/00006454-199406000-00033](https://doi.org/10.1097/00006454-199406000-00033)
- [5] M. Minami, Y. Wakimoto, M. Matsumoto, H. Matsui, Y. Kubota, A. Okada, M. Isaka, I. Tatsuno, Y. Tanaka and T. Hasegawa, "Characterization of *Streptococcus pyogenes* Isolated from Balanoposthitis Patients Presumably Transmitted by Penile-Oral Sexual Intercourse," *Current Microbiology*, Vol. 61, No. 2, 2010, pp. 101-105.
[doi:10.1007/s00284-010-9581-x](https://doi.org/10.1007/s00284-010-9581-x)
- [6] T. Hasegawa, S. N. Hashikawa, T. Nakamura, K. Torii and M. Ohta, "Factors Determining Prognosis in Streptococcal Toxic Shock-Like Syndrome: Results of a Nationwide Investigation in Japan," *Microbes and Infection*, Vol. 6, No. 12, 2004, pp. 1073-1077.
[doi:10.1016/j.micinf.2004.06.001](https://doi.org/10.1016/j.micinf.2004.06.001)
- [7] M. W. Cunningham, "Pathogenesis of Group A Streptococcal Infections," *Clinical Microbiology Reviews*, Vol. 13, No. 4, 2000, pp. 470-511.

- [doi:10.1128/CMR.13.3.470-511.2000](https://doi.org/10.1128/CMR.13.3.470-511.2000)
- [8] R. J. Olsen, S. A. Shelburne and J. M. Musser, "Molecular Mechanisms Underlying Group A Streptococcal Pathogenesis," *Cellular Microbiology*, Vol. 11, No. 1, 2009, pp. 1-12. [doi:10.1111/j.1462-5822.2008.01225.x](https://doi.org/10.1111/j.1462-5822.2008.01225.x)
- [9] A. L. Bricker, C. Cywes, C. D. Ashbaugh and M. R. Wessels, "NAD⁺-Glycohydrolase Acts as an Intracellular Toxin to Enhance the Extracellular Survival of Group A Streptococci," *Molecular Microbiology*, Vol. 44, No. 1, 2002, pp. 257-269. [doi:10.1046/j.1365-2958.2002.02876.x](https://doi.org/10.1046/j.1365-2958.2002.02876.x)
- [10] J. C. Madden, N. Ruiz and M. Caparon, "Cytolysin-Mediated Translocation (CMT): A Functional Equivalent of Type III Secretion in Gram-Positive Bacteria," *Cell*, Vol. 104, No. 1, 2001, pp. 143-152. [doi:10.1016/S0092-8674\(01\)00198-2](https://doi.org/10.1016/S0092-8674(01)00198-2)
- [11] M. A. Meehl, J. S. Pinkner, P. J. Anderson, S. J. Hultgren and M. G. Caparon, "A Novel Endogenous Inhibitor of the Secreted Streptococcal NAD-Glycohydrolase," *PLoS Pathogens*, Vol. 1, No. 4, 2005, p. e35. [doi:10.1371/journal.ppat.0010035](https://doi.org/10.1371/journal.ppat.0010035)
- [12] H. Kimoto, Y. Fujii, S. Hirano, Y. Yokota and A. Taketo, "Genetic and Biochemical Properties of Streptococcal NAD-Glycohydrolase Inhibitor," *Journal of Biological Chemistry*, Vol. 281, No. 14, 2006, pp. 9181-9189. [doi:10.1074/jbc.M506879200](https://doi.org/10.1074/jbc.M506879200)
- [13] R. Luttkicken, D. Luttkicken, D. R. Johnson and L. W. Wannamaker, "Application of a New Method for Detecting Streptococcal Nicotinamide Adenine Dinucleotide Glycohydrolase to Various M Types of *Streptococcus pyogenes*," *Journal of Clinical Microbiology*, Vol. 3, No. 5, 1976, pp. 533-536.
- [14] A. Michos, I. Gryllos, A. Hakansson, A. Srivastava, E. Kokkotou and M. R. Wessels, "Enhancement of Streptolysin O Activity and Intrinsic Cytotoxic Effects of the Group A Streptococcal Toxin, NAD-Glycohydrolase," *Journal of Biological Chemistry*, Vol. 281, No. 12, 2006, pp. 8216-8223. [doi:10.1074/jbc.M511674200](https://doi.org/10.1074/jbc.M511674200)
- [15] D. Ajdic, W. M. McShan, D. J. Savic, D. Gerlach and J. J. Ferretti, "The NAD-Glycohydrolase (*nga*) Gene of *Streptococcus pyogenes*," *FEMS Microbiology Letters*, Vol. 191, No. 2, 2000, pp. 235-241. [doi:10.1111/j.1574-6968.2000.tb09345.x](https://doi.org/10.1111/j.1574-6968.2000.tb09345.x)
- [16] T. Karasawa, K. Yamakawa, D. Tanaka, Y. Gyobu and S. Nakamura, "NAD(+)-Glycohydrolase Productivity of Haemolytic Streptococci Assayed by a Simple Fluorescent Method and Its Relation to T Serotype," *FEMS Microbiology Letters*, Vol. 128, No. 3, 1995, pp. 289-292. [doi:10.1111/j.1574-6968.1995.tb07538.x](https://doi.org/10.1111/j.1574-6968.1995.tb07538.x)
- [17] P. D. Lazarides and A. W. Bernheimer, "Association of Production of Diphosphopyridine Nucleotidase with Serological Type of Group A Streptococcus," *Journal of Bacteriology*, Vol. 74, No. 3, 1957, pp. 412-413.
- [18] I. Tatsuno, J. Sawai, A. Okamoto, M. Matsumoto, M. Minami, M. Isaka, M. Ohta and T. Hasegawa, "Characterization of the NAD-Glycohydrolase in Streptococcal Strains," *Microbiology*, Vol. 153, No. 12, 2007, pp. 4253-4260. [doi:10.1099/mic.0.2007/009555-0](https://doi.org/10.1099/mic.0.2007/009555-0)
- [19] D. J. Riddle, D. E. Bessen and M. G. Caparon, "Variation in *Streptococcus pyogenes* NAD⁺ Glycohydrolase Is Associated with Tissue Tropism," *Journal of Bacteriology*, Vol. 192, No. 14, 2010, pp. 3735-3746. [doi:10.1128/JB.00234-10](https://doi.org/10.1128/JB.00234-10)
- [20] I. Tatsuno, M. Isaka, M. Minami and T. Hasegawa, "NADase as a Target Molecule of *in Vivo* Suppression of the Toxicity in the Invasive M-1 Group A Streptococcal Isolates," *BMC Microbiology*, Vol. 10, 2010, p. 144. [doi:10.1186/1471-2180-10-144](https://doi.org/10.1186/1471-2180-10-144)
- [21] J. J. Ferretti, W. M. McShan, D. Ajdic, D. J. Savic, G. Savic, K. Lyon, C. Primeaux, S. Sezate, A. N. Suvorov, S. Kenton, H. S. Lai, S. P. Lin, Y. Qian, H. G. Jia, F. Z. Najjar, Q. Ren, H. Zhu, L. Song, J. White, X. Yuan, S. W. Clifton, B. A. Roe and R. McLaughlin, "Complete Genome Sequence of an M1 Strain of *Streptococcus pyogenes*," *Proceedings of the National Academy of Sciences of the United States of America*, Vol. 98, No. 8, 2001, pp. 4658-4663. [doi:10.1073/pnas.071559398](https://doi.org/10.1073/pnas.071559398)
- [22] A. N. Suvorov and J. J. Ferretti, "Physical and Genetic Chromosomal Map of an M Type 1 Strain of *Streptococcus pyogenes*," *Journal of Bacteriology*, Vol. 178, No. 18, 1996, pp. 5546-5549.
- [23] A. Podbielski, B. Spellerberg, M. Woischnik, B. Pohl and R. Luttkicken, "Novel Series of Plasmid Vectors for Gene Inactivation and Expression Analysis in Group A Streptococci (GAS)," *Gene*, Vol. 177, No. 1, 1996, pp. 137-147. [doi:10.1016/0378-1119\(96\)84178-3](https://doi.org/10.1016/0378-1119(96)84178-3)
- [24] S. Lukomski, N. P. Hoe, I. Abdi, J. Rurangirwa, P. Kordari, M. Liu, S. J. Dou, G. G. Adams and J. M. Musser, "Nonpolar Inactivation of the Hypervariable Streptococcal Inhibitor of Complement Gene(sic) in Serotype M1 *Streptococcus pyogenes* Significantly Decreases Mouse Mucosal Colonization," *Infection and Immunity*, Vol. 68, No. 2, 2000, pp. 535-542. [doi:10.1128/IAI.68.2.535-542.2000](https://doi.org/10.1128/IAI.68.2.535-542.2000)
- [25] C. D. Ashbaugh, H. B. Warren, V. J. Carey and M. R. Wessels MR, "Molecular Analysis of the Role of the Group A Streptococcal Cysteine Protease, Hyaluronic Acid Capsule, and M Protein in a Murine Model of Human Invasive Soft-Tissue Infection," *Journal of Clinical Investigation*, Vol. 102, No. 3, 1998, pp. 550-560. [doi:10.1172/JCI3065](https://doi.org/10.1172/JCI3065)
- [26] N. Okada, I. Tatsuno, E. Hanski, M. Caparon and Sasakawa C, "*Streptococcus pyogenes* Protein F Promotes Invasion of HeLa Cells," *Microbiology*, Vol. 144, No. 11, 1998, pp. 3079-3086. [doi:10.1099/00221287-144-11-3079](https://doi.org/10.1099/00221287-144-11-3079)

Supplement




Figure S1. Cloning of *Spn_{SF370}* gene into a pGEM[®]-T Easy Vector. Representative plasmids (pGEM-*spn_{SF370}*22 to 31) were shown. The pGEM-*spn_{SF370}*26 (lane number 26) possessed the correct size insert (1.5 kbp).




Figure S2. Physical map of *spn-ifs_{GT01}* genes. Used primers were shown as arrows.